Clinical trial
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared…
NCT00170469 · PharmAthene UK Limited, Industry · Completed
Key facts
| NCT number | NCT00170469 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed |
| Official title | A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population |
| Lead sponsor | PharmAthene UK Limited, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bacillus Anthracis (Anthrax) |
| Intervention type | Biological |
| Interventions | AVA, rPA vaccine containing alhydrogel |
| Enrollment | 226 |
| Start date | Mar 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 15, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: